Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
Healthcare
$0.46 -0.01%
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
52W Low $1.00High $3.06
Volume 2.23M
Average 1.99M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$49.04M
FY 2025 · Annual
Investing Cash Flow
$11.25M
FY 2025 · Annual
+35.8% YoYFinancing Cash Flow
$85.53M
FY 2025 · Annual
+166.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.06M) |
| Depreciation & Amortization | 362K | 89K | 92K | 105K | 114K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.28M | 9.05M | 9.53M | 5.78M | 7.46M |
| Change in Working Capital | 1.62M | (3.26M) | 1.24M | 3.66M | 2.68M |
| Accounts Receivables | 96K | (730K) | (2.64M) | 1.46M | (1.12M) |
| Inventory | 0 | 0 | 0 | 0 | (648K) |
| Accounts Payables | 0 | 0 | 0 | 0 | 4.43M |
| Other Working Capital | 1.52M | (2.53M) | 3.88M | 2.2M | 17K |
| Other Non-Cash Items | 368K | 44K | 2.39M | 3.13M | 3.76M |
| Operating Cash Flow | (33.22M) | (52.47M) | (46.42M) | (28.85M) | (49.04M) |
| Capital Expenditures | 0 | (272K) | (112K) | (33K) | (302K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (15M) | (85.85M) | (137.13M) | (113.55M) | (82.92M) |
| Sales of Investments | 85M | 29M | 142M | 121.87M | 94.47M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 70M | (57.12M) | 4.76M | 8.28M | 11.25M |
| Debt Repayment | 0 | 0 | 50M | 0 | 0 |
| Common Stock Issued | 0 | 2.63M | 0 | 27.26M | 85.53M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.06M | 458K | (2.21M) | 4.86M | 0 |
| Financing Cash Flow | 5.06M | 3.09M | 47.79M | 32.12M | 85.53M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.83M | (106.51M) | 6.12M | 11.55M | 47.73M |
| Free Cash Flow | (33.22M) | (52.74M) | (46.54M) | (28.88M) | (49.34M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$63.1M
+ D&A$114.0K
+ Stock-Based Comp$7.5M
+ Deferred Tax$0
+ Working Capital$2.7M
+ Other Non-Cash$3.8M
= Operating Cash Flow-$49.0M
- Capex-$302.0K
= Free Cash Flow-$49.3M
Analysis
FY2025 free cash flow is -$49.3M. FCF conversion is 78.3% of net income. Operating cash flow was -$49.0M, with capex of -$302.0K. The largest bridge item is Stock-Based Comp at $7.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 13, 2026 | |
| 8-K | Current report | Oct 28, 2026 | |
| 8-K | Current report | Sep 3, 2026 | |
| 8-K | Current report | Aug 12, 2026 |
Does MIST generate free cash flow?
Milestone Pharmaceuticals Inc. (MIST) generated -$49.34M of free cash flow in fiscal 2025.
How much operating cash flow does MIST produce?
Operating cash flow was -$49.04M, before capital expenditures of $302,000.00.
Continue the stock analysis
Jump to another research area for this company.